Brief: Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint
07/11/2023 12:14
Nov 7 (Reuters) - Akeso Inc 9926.HK :
* AKESO'S CADONILIMAB (PD-1/CTLA-4) PHASE III TRIAL MEETS
PRIMARY
ENDPOINT AT INTERIM ANALYSIS DEMONSTRATING STRONG OVERALL
SURVIVAL BENEFIT AS FIRST-LINE TREATMENT IN ALL-COMER PATIENTS
WITH GASTRIC CANCER OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
(GC/GEJC)
Source text for Eikon: ID:nPn9YnWJta
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals